Top Markets
#1 Useless Coin Useless Coin +41.99%
#2 StonkBroker StonkBroker +40.52%
#3 Merlin's Seal BTC Merlin's Seal BTC +37.86%
#4 0G 0G +33.36%
#5 SAFEcoin SAFEcoin +30.76%
#6 Zora Zora +23.17%
#7 Dogs Dogs +22.42%
#8 Full Moon Full Moon +19.59%
#9 ADO Protocol ADO Protocol +15.93%
#10 rsERG rsERG +15.87%
Coin of the day
Useless Coin Useless Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Evommune, Inc. Evommune, Inc.

Evommune, Inc.

EVMN
Rank in Stocks #13779
Evommune, Inc. is a United States-based clinical-stage biotechnology company... Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
Share Price
$12.63
Market Cap
$458.19M
Change (1 day)
-3.26%
Change (1 year)
-
Country
US
Trade Evommune, Inc. (EVMN)

Category

Healthcare
P/E ratio for Evommune, Inc. (EVMN)
P/E ratio as of 2026 TTM: 0
According to Evommune, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Evommune, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.